Mostrar el registro sencillo del ítem

dc.contributor.authorArconada Luque, Elena
dc.contributor.authorMuñoz Velasco, Raúl
dc.contributor.authorSánchez-Arévalo Lobo, Víctor
dc.contributor.authorRuiz Hidalgo, María José
dc.date.accessioned2022-09-13T12:06:02Z
dc.date.available2022-09-13T12:06:02Z
dc.date.issued2022
dc.identifier.issn2072-6694spa
dc.identifier.urihttp://hdl.handle.net/10641/3099
dc.description.abstractAbstract: Sarcomas are a heterogeneous group of tumors in which the role of ERK5 is poorly studied. To clarify the role of this MAPK in sarcomatous pathology, we used a murine 3-methyl-cholanthrene (3MC)-induced sarcoma model. Our data show that 3MC induces pleomorphic sarcomas with muscle differentiation, showing an increased expression of ERK5. Indeed, this upregulation was also observed in human sarcomas of muscular origin, such as leiomyosarcoma or rhabdomyosarcoma. Moreover, in cell lines derived from these 3MC-induced tumors, abrogation of Mapk7 expression by using specific shRNAs decreased in vitro growth and colony-forming capacity and led to a marked loss of tumor growth in vivo. In fact, transcriptomic profiling in ERK5 abrogated cell lines by RNAseq showed a deregulated gene expression pattern for key biological processes such as angiogenesis, migration, motility, etc., correlating with a better prognostic in human pathology. Finally, among the various differentially expressed genes, Klf2 is a key mediator of the biological effects of ERK5 as indicated by its specific interference, demonstrating that the ERK5–KLF2 axis is an important determinant of sarcoma biology that should be further studied in human pathology.spa
dc.language.isoengspa
dc.publisherCancersspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectSoft tissue sarcomaspa
dc.subjectLeiomyosarcomaspa
dc.subjectRhabdomyosarcomaspa
dc.subject3-methyl-cholanthrenespa
dc.titleERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology.spa
dc.typejournal articlespa
dc.type.hasVersionSMURspa
dc.rights.accessRightsopen accessspa
dc.description.extent9446 KBspa
dc.identifier.doi10.3390/cancers14143509spa
dc.relation.publisherversionhttps://www.mdpi.com/2072-6694/14/14/3509spa


Ficheros en el ítem

FicherosTamañoFormatoVer
3.-ERK5 Is a Major Determinant ...9.224MbPDFVer/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España